Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy

被引：5

作者：

Doubek, M ^{[1
]}

Brychtova, Y ^{[1
]}

Berkovcova, J ^{[1
]}

Krejci, M ^{[1
]}

Palasek, I ^{[1
]}

Dvorakova, D ^{[1
]}

Mayer, J ^{[1
]}

机构：

[1] Univ Hosp, Dept Internal Med Hematooncol, Ctr Mol Biol & Gene Therapy, Brno 62500, Czech Republic

来源：

LEUKEMIA | 2005年 / 19卷 / 05期

关键词：

D O I：

10.1038/sj.leu.2403708

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：885 / 888

页数：5

相关论文

共 7 条

[1] 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group [J].

Büchner, T ;

Hiddemann, W ;

Berdel, WE ;

Wörmann, B ;

Schoch, C ;

Fonatsch, C ;

Löffler, H ;

Haferlach, T ;

Ludwig, WD ;

Maschmeyer, G ;

Staib, P ;

Aul, C ;

Grüneisen, A ;

Lengfelder, E ;

Frickhofen, N ;

Kern, W ;

Serve, HL ;

Mesters, RM ;

Sauerland, MC ;

Heinecke, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4496-4504

[2] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[3] Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts [J].

Guerrasio, A ;

Pilatrino, C ;

De Micheli, D ;

Cilloni, D ;

Serra, A ;

Gottardi, E ;

Parziale, A ;

Marmont, F ;

Diverio, D ;

Divona, M ;

Lo Coco, F ;

Saglio, G .

LEUKEMIA, 2002, 16 (06) :1176-1181

[4] Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias [J].

Krauter, J ;

Görlich, K ;

Ottmann, O ;

Lübbert, M ;

Döhner, H ;

Heit, W ;

Kanz, L ;

Ganser, A ;

Heil, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4413-4422

[5]

MARUCCI G, 2002, LEUKEMIA, V15, P1072

[6] New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts [J].

Schnittger, S ;

Weisser, M ;

Schoch, C ;

Hiddemann, W ;

Haferlach, T ;

Kern, W .

BLOOD, 2003, 102 (08) :2746-2755

[7] Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement [J].

Viehmann, S ;

Teigler-Schlegel, A ;

Bruch, J ;

Langebrake, C ;

Reinhardt, D ;

Harbott, J .

LEUKEMIA, 2003, 17 (06) :1130-1136